Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis

ESMO Open(2024)10.1016/j.esmoop.2024.103660Source: DataRank Database

Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis is a research paper published in ESMO Open (2024). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.96)OA: goldTopics (62)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

B.Y. Yeap,Justin F. Gainor ORCID,Zofia Piotrowska ORCID

Live enrichment

PubMed:39168027 PMC:PMC11381989 OpenAlex:https://openalex.org/W4401793466

NCI NIH HHS

Grant: P50 CA265826

NCI NIH HHS

Grant: R01 CA137008

National Institutes of Health

Grant: 2R01CA137008-06

Impact of heterogeneity on response to EGFR T790M inhibitors

FWCI

1.96

Citation Percentile

0.8%

Influential Citations

Citation Trend

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.esmoop.2024.103660

GOLDhttps://doi.org/10.1016/j.esmoop.2024.103660

publisherhttps://doi.org/10.1016/j.esmoop.2024.103660

publisherhttps://api.elsevier.com/content/article/PII:S2059702924014297?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2059702924014297?httpAccept=text/plain

Fields of Study

Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentMedicine03 medical and health sciences0302 clinical medicineHumansCarcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsErbB ReceptorsB7-H1 AntigenDrug Resistance, NeoplasmImmune Checkpoint InhibitorsMutationProgrammed Cell Death 1 ReceptorAntineoplastic Combined Chemotherapy ProtocolsRandomized Controlled Trials as TopicTyrosine Kinase Inhibitors

MeSH Terms

Immune Checkpoint InhibitorsTyrosine Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsMutationRandomized Controlled Trials as TopicDrug Resistance, NeoplasmProtein Kinase InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorErbB Receptors

Keywords

ChemoimmunotherapyLung cancerMedicineOncologyEpidermal growth factor receptorInternal medicineGefitinibErlotinibHazard ratioCancer researchCancerImmunotherapyConfidence intervalEGFRMeta-analysisnon-small-cell lung cancerLung NeoplasmsProgrammed Cell Death 1 ReceptorTyrosine Kinase InhibitorsB7-H1 AntigenErbB ReceptorsDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungMutationAntineoplastic Combined Chemotherapy ProtocolsHumansProtein Kinase InhibitorsImmune Checkpoint InhibitorsOriginal ResearchRandomized Controlled Trials as Topic

Sustainable Development Goals

SDG 0: Good health and well-being

Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis

FAIR Checklist

Authors (3)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)